Glaukos (NYSE:GKOS) CFO Alex Thurman Sells 10,000 Shares

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 10,000 shares of Glaukos stock in a transaction on Thursday, July 16th. The stock was sold at an average price of $160.00, for a total transaction of $1,600,000.00. Following the sale, the chief financial officer owned 43,906 shares in the company, valued at $7,024,960. This represents a 18.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Price Performance

NYSE GKOS traded down $2.26 on Tuesday, reaching $149.65. The company’s stock had a trading volume of 324,799 shares, compared to its average volume of 854,495. The firm has a market cap of $8.79 billion, a PE ratio of -45.65 and a beta of 0.75. The business has a 50-day moving average price of $136.04 and a 200 day moving average price of $123.80. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $161.53. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. During the same quarter last year, the company earned ($0.22) earnings per share. The company’s revenue for the quarter was up 41.2% compared to the same quarter last year. Sell-side analysts expect that Glaukos Corporation will post -0.57 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. HC Wainwright started coverage on shares of Glaukos in a report on Monday, July 6th. They set a “buy” rating and a $168.00 price objective for the company. William Blair restated an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. Piper Sandler reaffirmed an “overweight” rating and set a $165.00 price target on shares of Glaukos in a report on Wednesday, July 1st. Stifel Nicolaus boosted their price objective on Glaukos from $170.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Finally, Truist Financial boosted their price objective on Glaukos from $160.00 to $180.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and a consensus price target of $155.23.

Institutional Investors Weigh In On Glaukos

Several large investors have recently made changes to their positions in the stock. First Horizon Corp raised its stake in shares of Glaukos by 1,715.4% in the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 223 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Glaukos in the 4th quarter valued at approximately $28,000. Larson Financial Group LLC lifted its stake in Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares during the last quarter. Parallel Advisors LLC grew its position in shares of Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 226 shares during the period. Finally, Farther Finance Advisors LLC grew its position in shares of Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 215 shares during the period. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.